Resistell

📍 Muttenz, Switzerland🗓 Founded 2017👥 33 employees💰 Last funded Dec 2023
Medical Equipment Manufacturing🌐 resistell.com
Website LinkedIn
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.
4
Total investors
3
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
3
United States
1
Investor activity2018–2023 · investors recorded per year
201812019220231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Resistell?
Resistell has 4 investors on record on gritt.io, including 3 early-stage backers and 1 late-stage investors.
When did Resistell last raise funding?
The most recent investment in Resistell recorded on gritt.io was in December 2023.
When was Resistell founded?
Resistell was founded in 2017.
What industry is Resistell in?
Resistell operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Resistell based?
Resistell is headquartered in Muttenz, Switzerland.